Literature DB >> 25458045

The impact of general anesthesia on radiofrequency ablation of hepatocellular carcinoma.

Yuan-Hung Kuo1, Kuan-Chih Chung2, Chao-Hung Hung1, Sheng-Nan Lu1, Jing-Houng Wang3.   

Abstract

This study investigates the impact of general anesthesia (GA) on percutaneous radiofrequency ablation (RFA) of hepatocellular carcinoma (HCC). A total of 118 treatment-naïve HCC patients in Barcelona Clinic Liver Cancer curative stage were enrolled. Patients who underwent RFA with GA were designated as the GA group, and the others were identified as the non-GA group. All the percutaneous RFA procedures were performed by the same hepatologist. The GA group comprised 42 (44.1%) patients with 71 tumors (mean size, 2.53 cm) and the non-GA group had 66 patients (55.9%) with 90 tumors (mean size, 2.35 cm). Complete tumor ablation was achieved after one session in 92.3% of the 52 GA patients, and after one to three sessions in 92.4% of 66 non-GA patients. The GA group required significantly fewer RFA sessions to obtain a similar treatment effect (p < 0.001) and the duration of hospitalization was also shortened among the GA patients (4.4 ± 0.9 days vs. 5.1 ± 1.9 days, p = 0.044). The 2-year overall survival and recurrence-free survival rates were not significantly different between the two groups. Overall, performing RFA with GA can decrease the number of sessions required to achieve complete tumor ablation in early stage HCC patients and shorten the hospitalization duration.
Copyright © 2014. Published by Elsevier Taiwan.

Entities:  

Keywords:  Barcelona Clinic Liver Cancer curative stage; General anesthesia; Hepatocellular carcinoma; Radiofrequency ablation

Mesh:

Year:  2014        PMID: 25458045     DOI: 10.1016/j.kjms.2014.07.001

Source DB:  PubMed          Journal:  Kaohsiung J Med Sci        ISSN: 1607-551X            Impact factor:   2.744


  4 in total

1.  Effects of general anesthesia versus local anesthesia in primary hepatocellular carcinoma patients presenting for thermal ablation surgery: a multiple center retrospective cohort study with propensity score matching.

Authors:  Xiaoqiang Wang; Weiying Xie; Shuyuan Gan; Tao Wang; Xuexin Chen; Diansan Su; Jiaxin Sun; Jiapiao Lin; Feixiang Wu; Pingbo Xu; Changhong Miao; Min Yan; Shengmei Zhu; Bo Zhai; Yuming Sun; Weifeng Yu; Jie Tian
Journal:  Ann Transl Med       Date:  2020-03

2.  Effects of Serum From Radiofrequency Ablation Patients Receiving General Anesthesia or Local Anesthesia on Hepatocellular Carcinoma Cancer Cell Malignancy: A Prospective Randomized Controlled Trial.

Authors:  Yumiao Shi; Tong Wu; Tao Wang; Yan Liu; Xiaoqiang Wang; Jiamei Luo; Diansan Su; Bo Zhai; Jie Tian
Journal:  Front Oncol       Date:  2021-09-23       Impact factor: 6.244

3.  The use of Esketamine in CT-guided percutaneous liver tumor ablation reduces the consumption of remifentanil: a randomized, controlled, double-blind trial.

Authors:  Yanbing Su; Jianxing Zhang; Huanwei Wang; Yangkui Gu; Handong Ouyang; Wan Huang
Journal:  Ann Transl Med       Date:  2022-06

4.  Different effects of oxycodone and remifentanil in patients undergoing ultrasound-guided percutaneous radiofrequency ablation of hepatic cancer: a randomized trial.

Authors:  Junbei Wu; Yunhong Lu; Xiaofei Cao
Journal:  Drug Des Devel Ther       Date:  2019-01-18       Impact factor: 4.162

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.